Pharma’s Q1 was a rollercoaster: overall revenues beat by 3%, stocks mostly rose, but Ocular Therapeutix tanked after missing badly—while Eli Lilly soared 50% YoY, crushing estimates and boosting its stock. Others like Amphastar stumbled, but Bristol-Myers and Jazz held strong, with Jazz showing explosive growth. The sector’s split reveals that innovation wins big, while misses face swift market punishment—look to AI and precision medicine for what’s next.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
